Avacta Group Plc (LON:AVCT) said a partner company will be presenting data on Avacta’s Affimer technology at a leading industry conference in Barcelona, which kicks off Wednesday.
Affimers are small, engineered proteins, some of which are of human origin and some plant-derived. They are capable of binding specific molecular targets, in a similar way to antibodies.
READ: Interest in Affimer technology at record levels, which bodes well for Avacta
The contract research firm Covance will be setting out new information that “highlights the validation of Affimer as a critical reagent in clinical assays when good batch-to-batch stability and reproducible performance are a regulatory requirement”.
Scientists attending the European Bioanalysis Forum will hear the update.
READ: Patient heal thyself - Avacta teams up with Finnish biotech firm to develop system that allows body to create its own drugs
Avacta’s chief executive, Dr Alastair Smith, said the presentation provided “strong, independent validation of the technical performance of Affimer reagents and is important to our commercialisation of the technology”.